The U.S. Food and Drug Administration (FDA) has granted orphan drug and rare pediatric disease designations to ART4, an experimental…
Articles by Lila Levinson, PhD
While different types of progressive familial intrahepatic cholestasis (PFIC) vary in their genetic cause and clinical profile, new medications…
Problems in mitochondria, the cell’s powerhouses, may contribute to liver damage associated with cholestasis and represent a potential therapeutic…
Regulators in the European Union (EU) have granted conditional approval to Rezdiffra (resmetirom) for some people with metabolic dysfunction-associated steatohepatitis…
Chemomab Therapeutics has aligned with U.S. regulators on several aspects of the late-stage development of nebokitug, its candidate therapy…
High maternal levels of liver damage markers in the blood can predict poor fetal outcomes in twin pregnancies affected by…
People with Alagille syndrome display different disease characteristics depending on whether the disease-causing mutation is located in the JAG1…
An unreported mutation in the JAG1 gene was identified as the likely cause of Alagille syndrome in a 28-year-old…
Hoth Therapeutics will support a U.S. Department of Veterans Affairs (VA) study testing treatment with glial cell-derived neurotrophic factor…
Combined treatment with phenobarbital and ursodeoxycholic acid (UDCA) is superior to phenobarbital alone at treating cholestasis symptoms, and does…